[Effect of fenformin and miscleron on the delayed hypersensitivity reaction in breast cancer patients].
Some preliminary results of using phenformin and miscleron in 17 breast cancer patients, previously radically operated upon, have been assessed as being characterized by metabolic disturbances associated with the reduced cell immunity level. The treatment of patients during 15--7 months was shown to result both in the correction of endocrine-metabolic disorders and stimulation of delayed hypersensitivity response, determined by skin tests with dinitro-chlorbenzene, tuberculin and Candida. The necessity to liquidate metabolic metabolic immunodepression with the aim of prophylaxis and treatment of the tuumor process is discussed. Some other routes of metabolic immunotherapy in addition to using phenformin and miscleron are considered. It seems rational to study the effect of a continuous administration of such kind of drugs on the results of treatment of oncological patients.
D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology*; D002994:Clofibrate / Q000008:administration & dosage / Q000276:immunology*; D004137:Dinitrochlorobenzene; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000188:drug therapy / Q000276:immunology*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000276:immunology*; D008875:Middle Aged; D010629:Phenformin / Q000008:administration & dosage / Q000276:immunology*; D012882:Skin Tests; D013997:Time Factors
D004137:Dinitrochlorobenzene; D000960:Hypolipidemic Agents; D010629:Phenformin; D002994:Clofibrate
Vliianie fenformina i misklerona na reaktsiiu giperchuvstvitel'nosti zamedlennogo tipa u bol'nykh rakom molochnoĭ zhelezy.